Inspira Technologies OXY B.H.N. Ltd. announced a partnership with Ennocure MedTech Ltd. At the core of Inspira's mission is a approach to oxygenate blood directly to replace life support mechanical ventilation. Inspira seeks to include bio-electronic technology as part of the INSPIRA ART and Company's IP portfolio, to prevent the growth of bacteria that often results in a bloodstream infection (sepsis) and has partnered with Ennocure for the development of such treatment. Once developed, Inspira plans to combine the bio-electronic novel physical stimulation technology, as a preemptive measure for potentially at-risk patients, providing a cost-competitive solution to reduce complications.
Inspira Technologies Oxy B.H.N. Ltd.
Equities
IINN
IL0011715781
Advanced Medical Equipment & Technology
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.2 USD | -2.22% | +8.18% | +112.27% |
1st Jan change | Capi. | |
---|---|---|
+112.27% | 38.91M | |
-5.89% | 3.13B | |
+3.80% | 188M | |
-14.58% | 84.35M | |
+13.04% | 51M | |
-53.29% | 50.99M |
- Stock Market
- Equities
- IINN Stock
- News Inspira Technologies Oxy B.H.N. Ltd.
- Inspira Collaborates with Ennocure for Development of Proprietary Bio-Electronic Treatment to Prevent Associated Bloodstream Infections in ICU Patients